Overwater Ventures led a $44m Series C funding round in Gameto.

Overwater Ventures, an early-stage venture capital firm backing breakthrough technologies that solve the world’s biggest problems, led a $44m Series C funding round in Gameto, a women's health biotechnology company advancing programs from a cell engineering platform developed with George Church's lab at Harvard Medical School, with participation from Insight Partners, RA Capital, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investment Partners, PAGS Group, Pontiva Healthcare Partners and Portfolia. "We believe Gameto has the potential to drive the biggest transformation in women's health since the birth control pill. We have yet to see another company with the rare combination of determination, breakthrough science, and the potential to create a strong consumer brand in biotech. At Overwater, we invest in category-defining technology, and few areas of healthcare are more overdue for reinvention than female biology itself. The implications and impact go far beyond reproduction. This is why we've written our largest check to date," Kristina Simmons, Overwater Ventures Founder and Managing Partner.